Brief: Medicus Pharma Submits Optimized Teverelix® Registrational Protocol To FDA To Create Partner Ready Program In Advanced Prostate Cancer
29/09/2026 12:32
BRIEF-Medicus Pharma Submits Optimized Teverelix® Registrational Protocol To FDA To Create Partner Ready Program In Advanced Prostate Cancer Sept 29 (Reuters) - Medicus Pharma Ltd MDCX.O:
MEDICUS PHARMA SUBMITS OPTIMIZED TEVERELIX® REGISTRATIONAL PROTOCOL TO FDA TO CREATE PARTNER READY PROGRAM IN ADVANCED PROSTATE CANCER
MEDICUS PHARMA - ANTICIPATES GMP MANUFACTURING AND STUDY READINESS COMPLETION BEFORE YEAR-END 2026
MEDICUS PHARMA - INTENDS TO SEEK STRATEGIC PARTNER OR OUT-LICENSE TEVERELIX APC PROGRAM
Source text: ID:nGNXLxNTt
Further company coverage: MDCX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Medicus Pharma
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Medicus Pharma Submits Optimized Teverelix® Registrational Protocol To FDA To Create Partner Ready Program In Advanced Prostate Cancer